Reports Q3 revenue $18.96M, consensus $18.85M. “Third quarter revenue of $19 million was the highest in TELA Bio’s (TELA) history and indicates a healthy demand for our products and a return to normalized growth across the OviTex portfolio following the second quarter’s external market disruptions,” said Antony Koblish, President and CEO of TELA Bio. “Our commercial leadership is prioritizing growth, and we are confident in our ability to demonstrate increased operating leverage going forward. With an additional $43 million in net proceeds following the recent underwritten public offering, and actions already taken to reduce operating expenses for 2025, we believe that we are amply funded to attain profitability with current resources.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TELA:
- TELA Bio Achieves Record Q3 Revenue Growth in 2024
- Tela Bio 12M share Spot Secondary priced at $2.25
- TELA Bio Reports Q3 2024 Preliminary Financial Results
- Tela Bio announces common stock offering, no amount given
- Tela Bio’s OviTex ‘primary beneficiary’ of BD settlement, says Lake Street
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
